导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.02% | 2197/4773 |
| 近一周 | -1.57% | 539/5462 |
| 近一月 | -1.19% | 876/5421 |
| 近一季 | -3.69% | 1450/5209 |
| 近半年 | -4.18% | 2451/4920 |
| 近一年 | 2.88% | 2031/4366 |
| 近两年 | 49.37% | 1483/2954 |
| 近三年 | 29.49% | 1074/2253 |
| 成立以来 | 118.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.01% 2062/4961 |
4.56% 2907/5312 |
- - |
- - |
| 2025 | 21.72% 2021/4813 |
-0.12% 2072/3635 |
5.53% 573/4076 |
12.57% 3062/4524 |
2.59% 904/4813 |
| 2024 | 11.64% 1307/3463 |
1.78% 854/2808 |
-2.02% 1129/3014 |
12.09% 2420/3129 |
-0.12% 1326/3463 |
| 2023 | 1.01% 376/2656 |
7.40% 581/2280 |
-0.69% 404/2385 |
-0.51% 422/2515 |
-4.81% 1179/2655 |
| 2022 | -12.38% 280/2207 |
-9.23% 316/1919 |
5.41% 908/2016 |
-9.86% 320/2113 |
1.59% 1207/2208 |
| 2021 | 5.45% 545/1822 |
-1.18% 445/1255 |
2.83% 988/1330 |
2.65% 433/1466 |
1.09% 1007/1822 |
| 2020 | 23.45% 654/1250 |
-7.08% 523/1028 |
10.85% 756/1067 |
10.53% 539/1164 |
8.45% 671/1184 |
| 2019 | 31.30% 471/1092 |
23.71% 543/754 |
-1.60% 320/804 |
1.43% 402/850 |
6.34% 623/918 |
| 2018 | -21.42% 212/834 |
- - |
- - |
- - |
-11.66% 334/691 |
| 2017 | 8.75% 312/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.69% 268/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.52% 167/575 |
- - |
- - |
- - |
- - |
| 2014 | 56.72% 48/237 |
- - |
- - |
- - |
- - |
| 2013 | -3.73% 81/186 |
- - |
- - |
- - |
- - |
| 2012 | 6.03% 72/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 上证综指ETF VS. 长安沪深300非周期A(740101) |